Bone loss stayed limited during treatment for early rheumatoid arthritis
Patients with early rheumatoid arthritis had limited bone-density loss during intensive treatment. Adding infliximab rather than placebo showed no statistically clear extra benefit; the whole regimen lacked a less intensive comparison.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Among patients with early rheumatoid arthritis receiving intensive combination treatment, bone mineral density declined little over follow-up. Adding infliximab initially did not produce a statistically clear advantage over placebo for bone loss. Because both groups received active background treatment, the study cannot show how that full regimen compares with less intensive care.
The abstract gives no numerical between-group bone-density estimate or uncertainty interval. Later therapies could be modified, which limits attribution of long-term patterns to the initial randomized addition.
What researchers found
Bone mineral density
During 10-year follow-up, infliximab versus placebo added to shared treatment showed no statistically significant between-group difference.
What bone density means
Bone mineral density measures the amount of mineral in bone. No new osteoporosis cases were reported, but fractures were not described. These results do not establish whether treatment prevented broken bones.
What the comparison tested
Both groups received arthritis medicines, prednisolone, calcium and vitamin D. Later treatment could change while targeting remission, meaning disease inactivity. The randomized question was whether adding infliximab improved bone-density outcomes.
The original publication
Limited reduction of bone mineral density in patients with early rheumatoid arthritis receiving aggressive treatment: 10 year results of the NEO-RACo study.
Sandström T, Kaipiainen-Seppänen O, Mali M et al.
Scand J Rheumatol · 2025
- PubMed ID
- 40548492
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.